Dynavax Technologies Corporation · Berkeley, CA United States (NASDAQ: DVAX)
| 2929 7th St., Ste. 100 | Phone: 510-848-5100 |
| Berkeley, CA | Fax: 510-848-1327 |
| 94710 | |
| United States | 
Map This Company |
Dynavax Technologies Corporation Rankings
Company Description
Dynavax Technologies is trying to reprogram the way the body reacts to disease. The firm focuses on immunostimulatory sequences (ISS), short strands of DNA found to strengthen the immune system. The company's lead candidate in clinical trials is HEPLISAV, a hepatitis B vaccine. Other candidates in the company's pipeline include a universal flu vaccine that would cover a wider span of flu viruses than traditional flu vaccines, as well as potential treatments for asthma, hepatitis C, and autoimmune and inflammatory diseases. To share the expense and risk of development, Dynavax has partnered with
Dynavax Technologies Corporation Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: DVAX Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 128 |
Executives
33 executives listed for Dynavax Technologies Corporation's Berkeley, CA location.
| Chairman | Arnold Oronsky | |
|---|---|---|
| CEO and Director | Dino Dina | |
| President, Chief Medical Officer, and Director | J. Tyler Martin |